SpineGuard SA

ENXTPA:ALSGD Stock Report

Market Cap: €11.5m

SpineGuard Valuation

Is ALSGD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALSGD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALSGD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALSGD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALSGD?

Key metric: As ALSGD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALSGD. This is calculated by dividing ALSGD's market cap by their current revenue.
What is ALSGD's PS Ratio?
PS Ratio2.5x
Sales€4.52m
Market Cap€11.49m

Price to Sales Ratio vs Peers

How does ALSGD's PS Ratio compare to its peers?

The above table shows the PS ratio for ALSGD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.5x
ALMKT Mauna Kea Technologies
1.4x8.0%€11.9m
ALBLU Bluelinea Société Anonyme
1.2xn/a€11.4m
ALDMS Diagnostic Medical Systems
0.3xn/a€13.6m
ALIKO Ikonisys
35.1x51.0%€15.8m
ALSGD SpineGuard
2.5xn/a€11.5m

Price-To-Sales vs Peers: ALSGD is good value based on its Price-To-Sales Ratio (2.5x) compared to the peer average (9.5x).

Price to Sales Ratio vs Industry

How does ALSGD's PS Ratio compare vs other companies in the FR Medical Equipment Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
GBT Guerbet
0.4x6.1%US$351.43m
ALBIO Biosynex
0.3xn/aUS$31.92m
ALDMS Diagnostic Medical Systems
0.3xn/aUS$14.28m
ALEMG Laboratoires Euromedis Société anonyme
0.4x8.3%US$13.69m
ALSGD 2.5xIndustry Avg. 3.5xNo. of Companies7PS02.44.87.29.612+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALSGD is good value based on its Price-To-Sales Ratio (2.5x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is ALSGD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALSGD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALSGD's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Equasens Société anonyme

€625.3m

Provides healthcare IT solutions in Europe.

EQS

€40.70

7D

-7.1%

1Y

-29.1%

Laboratoires Euromedis Société anonyme

€13.0m

Through its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand name for healthcare professionals, local communities, and individuals in France and internationally.

ALEMG

€4.57

7D

-3.6%

1Y

-4.2%

emeis Société anonyme

€901.5m

Operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.

EMEIS

€5.21

7D

-10.7%

1Y

-98.3%